Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, Massachusetts
- Most recent report
- 8-K, filed Aug 17, 2026
- Incorporated
- Delaware
- Filings on record
- 520 filings
- On EDGAR
- CIK 1680581
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company
Financials 8 of 32
News 8 of 84
Prospectuses and Registrations 8 of 37
- 424B3 Prospectus supplement for an offering Nov 4, 2026
- S-4/A Registration statement for a merger or exchange, amended Nov 3, 2026
- S-4/A Registration statement for a merger or exchange, amended Oct 20, 2026
- S-4/A Registration statement for a merger or exchange, amended Oct 8, 2026
- S-4 Registration statement for a merger or exchange Sep 2, 2026
- S-8 Registration statement for an employee plan Feb 24, 2026
- 424B5 Prospectus supplement for an offering Dec 11, 2025
- FWP Free writing prospectus Dec 10, 2025
Proxies 8 of 16
- DEFA14A Extra proxy material Apr 30, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2026
- DEFR14A May 7, 2025
- DEFA14A Extra proxy material Apr 30, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2025
- DEFA14A Extra proxy material Apr 19, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 19, 2024
- DEFA14A Extra proxy material Apr 28, 2023
Ownership 8 of 308
- SCHEDULE 13G/A Large holder reported a passive stake, amended Oct 28, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Oct 27, 2026
- 144 Notice of a proposed sale of restricted stock Sep 2, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 3, 2026
Other 8 of 43
- EFFECT Notice that a registration became effective Nov 4, 2026
- 425 Aug 17, 2026
- 425 Aug 17, 2026
- 425 Aug 17, 2026
- ARS Annual report sent to shareholders Apr 30, 2026
- ARS Annual report sent to shareholders Apr 30, 2025
- EFFECT Notice that a registration became effective Apr 25, 2024
- CORRESP Reply to SEC staff Apr 24, 2024
Everything here comes from Fulcrum Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.